P591 : Treatment of recalcitrant pyoderma gangrenosum with ulcerative colitis by adalimumab (Humira®) injection
저작시기 2015.01|등록일 2015.06.15어도비 PDF (pdf)|1페이지|가격 1,000원
* 본 문서는 배포용으로 복사 및 편집이 불가합니다.
ㆍ발행기관 : 대한피부과학회ㆍ수록지정보 : 프로그램북(구 초록집) / 67권 / 1호 ㆍ저자명 : ( In Kyu Chang ) , ( Hae Eul Lee ) , ( Myung Im ) , ( Young Joon Seo ) , ( Jeung Hoon Lee ) , ( Young Lee )
Pyoderma gangrenosum (PG) is a rare ulcerative cutaneous condition that is associated with systemic disease. We report a case of a 20-year-old woman with severe recalcitrant PG and ulcerative colitis who was successfully treated by adalimumab injection. After she was diagnosed with PG, her skin lesions persisted despite treatment with oral prednisolone and cyclosporine. Therefore, we started treatment with etanercept (50 mg twice weekly), and observed dramatic improvement of the ulcer. Unfortunately, after one year, the skin lesions worsened even with etanercept treatment. Adalimumab was then administered at a dose of 80 mg in week 0 and 40 mg in week 1, followed by 40 mg every second week. After the second dose of adalimumab, rapid clinical improvement was observed, with complete PG healing after 8 weeks of treatment. Since the last (ninth) treatment, the therapeutic effect has been maintained for about 6 months. The successful treatment of PG in our patient suggests that adalimumab may be a valuable therapeutic option for PG among ulcerative colitis patients who fail to respond to etanercept and other conventional immunosuppressive regimens.